A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.

Date publication

août 2015

Journal

Journal of clinical pharmacy and therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MOUNIER Morgane , Dr CHRETIEN Marie-Lorraine

Tous les auteurs :
Lang AS, Mounier M, Roques M, Chretien ML, Boulin M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25865674

Résumé

Since their introduction, tyrosine kinase inhibitors (TKIs) have been increasingly used in clinical practice. We describe the prescribing and the clinical and biological consequences of two such inhibitors, imatinib and erlotinib, in patients with chronic myeloid leukaemia (CML) in a practice setting over a period of more than 10 years.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, adverse effects, Erlotinib Hydrochloride, adverse effects, Female, Follow-Up Studies, Hospitals, University, Humans, Imatinib Mesylate, adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Male, Middle Aged, Practice Patterns, Physicians', Protein Kinase Inhibitors, adverse effects, Retrospective Studies, Treatment Outcome, Young Adult

Référence

J Clin Pharm Ther. 2015 Aug;40(4):391-7